

BIO-GENE Shareholder Newsletter and Teleconference

Bio-Gene Technology Limited (ASX: BGT), today published a shareholder newsletter which can be accessed on Bio-Gene's investor relations website at: www.bio-gene.com.au/investor-relations/shareholder-updates/

Bio-Gene CEO, Richard Jagger will host a teleconference with investors to provide an update on the Company's progress at 2.30pm on Wednesday 27th March.

Questions can be submitted prior to the call to: bgt.shareholder@bio-gene.com.au

Call Details:

Australia: 02 8373 3582
Conference ID: 5098863

In the 10 minutes prior to the call start time, dial in using the numbers listed above.
An operator will greet you and ask for the Conference ID shown above.

A recording of the teleconference will be available at:
<https://bio-gene.com.au/investor-relations/corporate-presentations/>

- ENDS -

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Roger McPherson
CFO & Company Secretary
P: 03 9628 4178
E: bgt.info@bio-gene.com.au

Media/investor relations:

Davina Gunn
Henslow
T: 0400 896 809
E: dgunn@henslow.com

About Bio-Gene Technology Limited

Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones. Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across animal health and crop protection, as well as in public health, and in consumer applications. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.